Publication Name	World Journal of Clinical Cases
Manuscript ID	91615
Country	Croatia

Received	2023-12-31 17:51
Peer-Review Started	2023-12-31 17:51
First Decision by Editorial Office Director	2024-01-09 02:11
Return for Revision	2024-01-10 23:32
Revised	2024-01-25 22:16
Publication Fee Transferred
Second Decision by Editor	2024-03-14 04:25
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2024-03-14 07:07
Articles in Press	2024-03-14 07:07
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-25 10:12
Publish the Manuscript Online	2024-04-02 09:09

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Discontinuation of therapy in inflammatory bowel disease: Current views
Manuscript Source	Invited Manuscript
All Author List	Antonio Meštrović, Marko Kumric and Josko Bozic
ORCID	Author(s) ORCID Number Antonio Meštrović http://orcid.org/0000-0002-0156-2748 Marko Kumric http://orcid.org/0000-0002-9696-3359 Josko Bozic http://orcid.org/0000-0003-1634-0635
Funding Agency and Grant Number
Corresponding Author	Josko Bozic, MD, PhD, Associate Professor, Department of Pathophysiology, University of Split School of Medicine, Soltanska 2, Split 21000, Croatia. josko.bozic@mefst.hr
Key Words	Inflammatory bowel disease; Therapy discontinuation; Therapy de-escalation; Ulcerative colitis; Crohn’s disease
Core Tip	Tailoring treatment for inflammatory bowel disease (IBD) hinges on timely drug initiation aligned with treatment objectives. While therapy approaches evolve, achieving and sustaining remission prompts discussions on de-escalating or halting treatment, weighed against long-term therapy risks. With each IBD drug category, relapse risks persist post-discontinuation, impacting over 50% of patients. Withdrawal following combination therapies shows prolonged relapse-free periods, yet randomized trials on medication cessation are limited. Identifying relapse predictors and suitable candidates is pivotal. Re-treatment success underpins therapy withdrawal decisions. Individualized assessments, considering disease severity, duration, side effects, relapse risk, and patient preferences all guide prudent discontinuation choices.
Publish Date	2024-04-02 09:09
Citation	Meštrović A, Kumric M, Bozic J. Discontinuation of therapy in inflammatory bowel disease: Current views. World J Clin Cases 2024; 12(10): 1718-1727
URL	https://www.wjgnet.com/2307-8960/full/v12/i10/1718.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i10.1718

Full Article (PDF)	WJCC-12-1718-with-cover.pdf
Manuscript File	91615_Auto_Edited-YJP.docx
Answering Reviewers	91615-Answering reviewers.pdf
Audio Core Tip	91615-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	91615-Conflict-of-interest statement.pdf
Copyright License Agreement	91615-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	91615-Language certificate.pdf
Scientific Misconduct Check	91615-Bing-Zhang L-2.png
CrossCheck Report	91615-CrossCheck report.pdf
CrossCheck Report	91615-CrossCheck.png